Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Addiction Science & Clinical Practice ; 17(1):66, 2022.
Article in English | MEDLINE | ID: covidwho-2139412

ABSTRACT

BACKGROUND: Approximately 80% of people with a substance use disorder (SUD) are smokers. Starting SUD treatment offers the opportunity to also quit smoking. The ACT-ATAC project aims to identify the predictors associated with smoking cessation among persons treated for alcohol and/or cannabis use disorder in Barcelona. This manuscript reports its methodology and the experience of carrying it out during the COVID-19 pandemic.

2.
Jimenez, S.; Miro, O.; Alquezar-Arbe, A.; Pinera, P.; Jacob, J.; Llorens, P.; Garcia-Lamberechts, E. J.; Martin-Sanchez, F. J.; Del Castillo, J. G.; Burillo-Putze, G.; Martin, A.; Grima, M. L. L.; Gomez, M. A. J.; Millan, J.; Lazaro, L. S.; Espinosa, B.; Paya, A. B.; Noceda, J.; Cano, M. J. C.; Serra, R. S.; Bayarri, M. J. F.; Suarez, F. J. S.; Tejera, M. G.; Porrino, J. M. M.; Maestre, M. R.; Melendez, N.; Albero, P. B.; Escolano, E. R.; Manrique, K. J. A.; Del Rio, R.; Mestre, A. M.; Garcia, C. P.; Amador, P. S.; Aznar, J. V. B.; Lopez, J. L. R.; Ponce, M. C.; Belda, M. B. R.; Fernandez, E. D.; Valero, C. C.; Gimenez, L. M.; Gomez, A. P.; Bellver, E. G.; Rizzi, M.; Suarez, C. C.; Cardozo, C.; Llopis-Roca, F.; Roset-Rigat, A.; Boter, N. R.; Rovira, M. A.; Tost, J.; Tejedo, A. A.; Lorenzo, I. C.; Palau-Vendrell, A.; Tur, R. G.; Munoz, M. A.; Ferrer, E. S.; Garcia, L. L.; Mojarro, E. M.; Jimenez, B. S. A.; Huerta, A.; Fragiel, M.; Quiros, A. M.; Del Val, E. M.; Del Arco Galan, C.; Jimenez, G. F.; Garate, R. T.; Borrego, B. V.; Arias, A. S.; Cabezas, V. P.; Aviles, R. M.; Gonzalez, S. R.; Ramos, M. E. B.; Alonso, M. A.; Martin-Borregon Bendito, P.; Aguado, A. C.; Martin, S. G.; Somohano, F. V.; Lopez-Laguna, N.; Panadero, R. P.; De Frutos, M. F.; Robledo, F. D.; Madrigal, A. A.; Castaneda, A. B.; Diez, M. P. L.; Izquierdo, R. L.; Ruperez, I. G.; Chaib, F. B.; Abdelkader, I. S. M.; Rafael, I. R.; Tornero, A. P.; Soriano, J. J. C.; Perez, E. M.; Urbano, C. A.; Soto, A. B. G.; Garcia, J. P.; De Simon Almela, A. F.; Lopez, R. C.; Diaz, J. J. L.; Vera, M. T. M.; Calveiro, R. R.; Lucas-Imbernon, F. J.; Moreno, M. R.; Martinez, F. G.; Olmeda, D. M.; Juarez, R.; Hernandez, P. E.; Rodriguez, M. E.; Monzo, J. P.; Gonzalez, N. C.; Herrera, D. M. V.; Bautista, B. M. M.; Alvarez, L. A.; Hevia, M. D. R. C.; Motto, E. Q.; Garcia, N. T.; Diaz, N. M.; Mercader, M. P. O.; De Lobera, N. R.; Amez, J. M. F.; Entrala, B. A..
Emergencias ; 34(5):369-376, 2022.
Article in Spanish | EMBASE | ID: covidwho-2111934

ABSTRACT

Objectives. To define quality of care indicators and care process standards for treating patients with COVID-19 in hospital emergency departments (EDs), to determine the level of adherence to standards during the first wave in 2020, and to detect factors associated with different levels of adherence. Methods. We selected care indicators and standards by applying the Delphi method. We then analyzed the level of adherence in the SIESTA cohort (registered by the Spanish Investigators in Emergency Situations Team). This cohort was comprised of patients with COVID-19 treated in 62 Spanish hospitals in March and April 2020. Adherence was compared according to pandemic-related ED caseload pressure, time periods during the wave (earlier and later), and age groups. Results. Fourteen quality indicators were identified. Three were adhered to in less than 50% of the patients. Polymerase chain reaction testing for SARS-CoV-2 infection was the indicator most often disregarded, in 29% of patients when the caseload was high vs 40% at other times (P <.001) and in 30% of patients in the later period vs 37% in the earlier period (P =.04). Adherence to the following indicators was better in the later part of the wave: Monitoring of oxygen saturation (100% vs 99%, P =.035), electrocardiogram monitoring in patients treated with hydroxychloroquine (87% vs 65%, P <.001), and avoiding of lopinavir/ritonavir treatment in patients with diarrhea (79% vs 53%, P <.001). No differences related to age groups were found. Conclusions. Adherence to certain quality indicators deteriorated during ED treatment of patients with COVID-19 during the first wave of the pandemic. Pressure from high caseloads may have exacerbated this deterioration. A learning effect led to improvement. No differences related to patient age were detected. Copyright © 2022, Saned. All rights reserved.

3.
Emergencias ; 34(6):428-436, 2022.
Article in Spanish | EMBASE | ID: covidwho-2111909

ABSTRACT

Objective. To describe the sociodemographic characteristics, comorbidity, and baseline functional status of patients aged 65 or older who came to hospital emergency departments (EDs) during the first wave of the COVID-19 pandemic, and to compare them with the findings for an earlier period to analyze factors of the index episode that were related to mortality. Methods. We studied data from the EDEN-COVID cohort (Emergency Department and Elder Needs During COVID-19) of patients aged 65 years or older treated in 40 Spanish EDs on 7 consecutive days. Nine sociodemographic variables, 18 comorbidities, and 7 function variables were registered and compared with the findings for the EDEN cohort of patients included with the same criteria and treated a year earlier in the same EDs . In-hospital mortality was calculated in the 2 cohorts and a multivariable logistic regression model was used to explore associated factors. Results. The EDEN-COVID cohort included 6806 patients with a median age of 78 years;49% were women. The pandemic cohort had a higher proportion of men, patients covered by the national health care system, patients brought from residential facilities, and patients who arrived in an ambulance equipped for advanced life support. Pandemic-cohort patients more often had diabetes mellitus, chronic kidney disease, and dementia;they less often had connective tissue and thromboembolic diseases. The Barthel and Charlson indices were worse in this period, and cognitive decline was more common. Fewer patients had a history of depression or falls. Eight hundred ninety these patients (13.1%) died, 122 of them in the ED (1.8%);these percentages were lower in the earlier EDEN cohort, at 3.1% and 0.5%, respectively. Independent sociodemographic factors associated with higher mortality were transport by ambulance, older age, male sex, and living in a residential facility. Mortalityassociated comorbidities were neoplasms, chronic kidney disease, and heart failure. The only function variable associated with mortality was the inability to walk independently. A history of falls in the past 6 months was a protective factor. Conclusions. The sociodemographic characteristics, comorbidity, and functional status of patients aged 65 years or older who were treated in hospital EDs during the pandemic differed in many ways from those usually seen in this older-age population. Mortality was higher than in the prepandemic period. Certain sociodemographic, comorbidity, and function variables were associated with in-hospital mortality. Copyright © 2022, Saned. All rights reserved.

5.
Environmental Research ; : 114443, 2022.
Article in English | MEDLINE | ID: covidwho-2049189

ABSTRACT

INTRODUCTION: The Angiotensin-Converting Enzyme 2 (ACE2) is the main receptor of the SARS-CoV-2. There is contradictory evidence on how the exposure to nicotine may module the concentration of soluble ACE2 (sACE2). The aim of this study was to assess the association between nicotine and sACE2 concentrations in saliva samples. METHODS: Pooled analysis performed with data retrieved from two studies (n=634 and n=302). Geometric mean (GM) concentrations of sACE2, both total and relative to the total amount of protein in the sample, were compared according to sociodemographic variables and variables associated to nicotine. Multivariable linear regression models were fitted to explore the associations of sACE2 with nicotine adjusting for sex, age and body mass index. Spearman's rank-correlation coefficients were estimated between the concentrations of nicotine and cotinine, and pack-years, the concentration of relative sACE2 and the isoforms of sACE2. RESULTS: We observed a significant increase of 0.108 and 0.087ng/mul in the relative and absolute salivary sACE2 GM concentrations, respectively, between the lowest and highest nicotine levels. Similar results were observed for cotinine. These associations did not change in the multivariable linear models. There was a low correlation of nicotine and cotinine concentration with the concentration of relative salivary sACE2 (rs=0.153 and rs=0.132, respectively), pack-years (rs=0.222 and rs=0.235, respectively) and with the concentration of isoform 40KDa (rs=0.193 and rs=0.140, respectively). CONCLUSION: Salivary nicotine concentration seems to be limitedly associated with the concentration of sACE2.

6.
Addiction Research and Theory ; 2022.
Article in English | Scopus | ID: covidwho-2017448

ABSTRACT

Background: We aimed to assess whether stress, boredom, drinking motives, and/or inhibitory control were related to alcohol use during a period of social isolation. Method: Analyses were carried out on questionnaire data (N = 337) collected during the first wave of the COVID-19 pandemic (7 April–3 May 2020). We first assessed changes in drinking behavior, stress and boredom. We then regressed drinking behavior on drinking motives, inhibitory control, stress, and boredom. We also investigated interactions between change in stress/boredom and inhibitory control. Results: A minority of respondents reported increased alcohol use (units = 23.52%, drinking days = 20.73%, heavy days = 7.06%), alcohol-related problems (9.67%), and stress (36.63%). Meanwhile, most respondents reported increased boredom (67.42%). Similarly, boredom significantly increased (B = 21.22, p <.001), on average, while alcohol-related problems decreased (B = −1.43 p <.001). Regarding drinking motives, decreased alcohol-related problems were associated with social drinking motives (B = −0.09, p =.005). Surprisingly, risk-taking was associated with decreased alcohol-related problems (B = −0.02, p =.008) and neither stress nor boredom independently predicted changes in alcohol use. Finally, several significant interactions suggested that those who were more impulsive and less bored were more likely to report increased alcohol use and vice versa. Conclusions: These data provide a nuanced overview of changes in drinking-related behavior during the COVID-19-induced period of social isolation. While most people reduced their drinking, there was evidence of complex interactions between impulsivity and boredom that may be explored in future studies. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

7.
Annals of the Rheumatic Diseases ; 81:974-975, 2022.
Article in English | EMBASE | ID: covidwho-2009166

ABSTRACT

Background: Vaccination against SARS-CoV-2 has shown efficacy and safety in patients with chronic infammatory rheumatic disease, similar to the general population. However, in patients treated with rituximab (RTX) it is known that usually have a lower vaccination response rate (1-2), and recent studies suggest that it also happens with the new SARS-CoV 2 vaccine (3), which entails an increased risk of hospitalization and mortality in this specifc group of patients. Objectives: To describe humoral immune response to SARS-CoV-2 vaccine in rituximab-treated patients after one and six months from the vaccination, and study if there is any other factor associated with a lower response rate. Methods: Prospective analysis of a cohort of patients treated with RTX who received the SARS-CoV-2 vaccine between the months of April and October 2021. Demographic and medical data were collected through electronic medical records. Blood tests and serologies with levels of antibodies against SARS-CoV-2 were performed one and six months after having received the vaccine against SARS-CoV-2. The administration of a booster dose of the vaccine was recorded. A descriptive and statistical analysis of the data was carried out using the SPSS program. Results: From a cohort of 41 patients, of whom 81,4% were women with a mean age of 56 (13,4 SD) years, vaccine response rate was only 36,7% after a 6-month follow-up. The 88,4% of them received a booster dose of the vaccine, but this failed to produce a vaccine response in any of the patients who had not developed it with the previous ones. One patient became infected after receiving one dose of the vaccine and failed to develop a serological response either. Hypogammaglobulinemia was associated with a statistically signifcant lower probability of vaccine response (p=0,04). A trend of lower vaccination response rate was observed in patients who had received the last cycle of RTX in the 6 months prior to vaccination (p=0,058). In addition, the antibody levels developed one month after vaccination were statistically signifcantly correlated with the time between the last RTX cycle and vaccination (p=0,014) and also with CD19 B cells levels prior to vaccination (p<0,001);however, there was no correlation with the antibody levels detected at the 6-months serology. No statistically signifcant differences were found in relation to the number of previous cycles of RTX, concomitant treatment with synthetic disease-modifying drugs (DMARDs) or corticosteroids. Conclusion: In our sample, after a 6-month follow-up only 36,9% achieved a vaccine response against SARS-CoV-2, which did not improve despite the administration of a booster dose. Hypogammaglobulinemia, the time between the last RTX cycle and vaccination (at least 6 months), and previous CD19 B cells levels signifcantly influenced in the development of a humoral response to the vaccine.

8.
Annals of the Rheumatic Diseases ; 81:374, 2022.
Article in English | EMBASE | ID: covidwho-2008943

ABSTRACT

Background: The relevance of studying immune response after SARS-CoV-2 vaccination in patients with infammatory immune-mediated diseases (IMIDs) represents a deep concern regarding the risk estimation and management of patients with these diseases on immunomodulatory drugs. It is well known that certain treatments as anti CD20 therapies results in a diminished immunogenicity against common vaccines but it is a scarce data regarding the cellular protection obtained upon vaccination between patients with different IMID and between different treatments. Objectives: To compare a potential detriment on cellular and antibody-mediated protection upon SARS-CoV-2 vaccination in patients with IMIDs treated with immunosuppressive drugs. Methods: We recruited 73 patients with rheumatoid arthritis-RA-(n=49), spondy-larthritis-SpA-(n=19), infammatory bowel disease-IBD-(n=5), idiopathic juvenile arthritis-IJA-(n=2) and heterogenous group composed of sclerodermia, lupus, uveitis(n=6). They were treated mainly with rituximab (n=27), TNFi (n=37) or JAKi (n=3). We collected data of age,sex, csDMARDs, previous SARS-CoV-2 infection, last RTX infusion and prednisone use. After one month of vaccination, we assessed the humoral response performing the Thermo Scientific EliA SARS-CoV-2-Sp1 IgG Test (positivity cut-off >0.70 IU/ml) which was also compared with the data with of 35 healthy controls. In addition, in 40 patients who had serum antibody levels under 100UI/ml, we analysed the cellular response by the use of the QuantiFERON SARS-CoV-2 Starter Pack (Quiagen). A cut-off value of 0.15 IU/ml discriminate between positive or negative cell-mediated immune responses. We compared differences among the different IMIDs and between the different immu-nosuppressive treatments through non-parametric test (p<0.05) Results: Regarding demographic characteristics of patients, older patients (>56 years) and female sex were factors which were associated with low titles of serum antibodies. Anti-spike IgG antibodies were present in an 86% of the IMIDs patients and in 100% healthy controls with signifcant different IgG titre (median [IQR]): 51[11-184] vs 700[440-940];p<0.0001. The differences between (median [IQR]) serum antibody levels were statistically different between IMID type: 33[1-138] in RA vs 94[34-191] in SpA vs 204[187-204] in IBD vs 133[61-204] in IJA vs 13[1.5-31.8] in the rest;p=0.04. Remarkably, patients with IBD who had the highest antibodies titles were the youngest compared with the other patients. Target of the therapy played also an important role in serum antibody levels being these: 3.6 [0.7-51] in RTX patients vs 156 [45-204] in TNFi vs 40 [18-58] in JAKi patients;p<0.0001. In those patients who the last infusion of rituximab was, at least, one year before vaccination presented CD19+ B cells detected by fow cytometry and anti-spike IgG antibodies as well. Cell-mediated responses to SARS-CoV-2 were positive in 33% of IMIDs patients, indeterminated in 3% and negative in 65% of the patients. Strikingly, out of the 33% positive patients, 85% were treated with RTX. A 61% of the RTX patients had inducible cell-mediated responses vs 14% of the patients treated with TNFi;p<0.01. On the other hand, there were not differences in cell-mediated responses between positive and negative antibody patients. Conclusion: Titres of serum antibodies against spike protein of SARS-CoV-2 were lower in IMIDs patients than in controls. Patients with RTX had lower rates of positivity humoral response as well as lower serum titles than patients treated with other therapies regardless the patients 'age. Neverthless, in those patients in whom RTX infusion was delayed because of vaccination they conserved a humoral response. On the other hand, more patients treated with RTX had inducible cell-mediated responses compared with patients with TNFi.

9.
Acta Otorrinolaringologica Espanola ; 2022.
Article in English | EMBASE | ID: covidwho-2004401

ABSTRACT

Background and objective: The care of tracheostomized patients are high risk skills and low incidence. Strategies for improvement of health care in hospital wards and specialties other than otolaryngology based solely on training have not been able to offer an adequate solution. A tracheostomized patient unit is presented directed by the otolaryngology service to attend all tracheostomized hospitalized patients of all specialties. Material and methods: Background: Third level public hospital with 876 hospitalization beds and 30 ICU beds for 481,296 inhabitants. Unit model: Transversal unit for the hospital providing attention to all tracheostomized patients, adults, and children, of all specialties, with dedication of 50% of a ENT nurse of hospitalization that moves to the hospitalization bed of the specialty of each patient and 50% of another office ENT nurse for ambulatory patients care, with the consultancy of an ENT specialist and coordinated by the ENT supervisor. Results: 572 patients between 2016 and 2021, 80% men, aged 63 ± 14 years, were attended in the unit. 14.7 ± 2 tracheostomized patients daily and 96 ± 4 complication annual consultations were attended, rising up to 19 tracheostomized patients daily by 2020 and 141 ± 8.4 consultations by complications in 2020 and 2021, during the COVID-19 pandemic. The mean stay of the non-ENT specialties was reduced in 13 days, increasing the satisfaction of the ENT and non-ENT professionals and the satisfaction of the users. Conclusions: A Tracheostomized Patient Care Unit proactively directed from the Otorhinolaryngology Service to transversally care for all tracheostomized patients improves the quality of health care by reducing stay, complications, and emergencies. Improves the satisfaction of non-otolaryngological professionals by reducing the anxiety of facing care of patients who lack knowledge and experience and that of ENT specialists and nurses by reducing unplanned extemporaneous demands for care. Improves user satisfaction by perceiving adequate continuity of care. The Otorhinolaryngology Services provide their experience in the management of laryngectomized and tracheostomized patients and in teamwork with other specialists and professionals without the need to create new structures outside otorhinolaryngology.

10.
Prisma Social ; - (38):221-243, 2022.
Article in English | Web of Science | ID: covidwho-2003348

ABSTRACT

The global crisis in the flow of information and communications due to COVID-19, infodemia, largely caused by social networks, has left a global concern about the impact of fake news on societies. The increase in the consumption of networks and the presence of the population in these spaces impose the need to know how to adequately address this social problem, which involves the management of digital identity and network consumption habits. In this sense, the study presented here, of an exploratory nature and with the philosophy of exploration-action, has the dual objective of exploring the perceptions, uses and consumption of digital identity, social networks, and fake news in order, secondly, to propose specific actions. The research is approached with a quantitative, descriptive, and correlational methodology in a sample of 248 master's and bachelor's degree students from 17 different autonomous communities. The results indicate a significant lack of knowledge despite the degree of use and consumption, revealing the need for specific actions that require specific digital literacy. In the conclusions, the training axes are provided as a proposal for innovative intervention to be taught in the university environment in a crosscutting manner.

11.
Journal of General Internal Medicine ; 37:S196, 2022.
Article in English | EMBASE | ID: covidwho-1995598

ABSTRACT

BACKGROUND: Underuse of interpretation services for Limited English Proficiency (LEP) patients has been both widely reported in popularmedia and is increasingly documented in the literature. The COVID-19 pandemic has affected every aspect of healthcare and has directly impacted the use of interpreters with barriers such as strict visitation policies, limited patient interactions with healthcare workers, and withdrawal of in-person interpreters from the hospital setting. In this study we assess the use of interpreter services by healthcare professionals (HCPs) for LEP patients at an academic teaching hospital during the pandemic. METHODS: A combination of quantitative and qualitative data was obtained, and a total of 107 HCPs responded to the survey between August and October 2021. The majority of respondents were physicians (50.4%) and the largest specialties represented were Internal Medicine, Hospital Medicine, and medical subspecialties (36.4%). RESULTS: Study participants reported a preference for digital interpreters. Despite affirming the importance of interpretation services for LEP patients and endorsing the use of telephone and tablet digital methods, many HCPs cite hassle and time constraints as limiting factors for the use of interpreter services. HCPs reported wide variation in use of interpretation services based on type of encounter. Of HCPs who assessed themselves as non-fluent in Spanish, 71% reported patient encounters without interpretation services, with some reporting they “know enough Spanish to get through”. When asked to rank their likely use of interpretation services in different clinical settings, 88% stated they use interpretation in “Goals of Care Meetings”, 87%use them when “Consenting Patients”, and 80% use them for the initial encounters. However, only 47% and 51% stated that they used interpreters for follow-up encounters and consult visits, respectively. Only 25% reported using interpreters for other visits. CONCLUSIONS: The COVID-19 Pandemic has hastened a shift to digital platforms in many arenas, and healthcare interpretation services have been equally affected. However, despite hopes that digital or telephonic means of interpretation would improve interpretation use by HCPs, our study shows that HCPs continue to use these services at inadequate rates. Time constraints, hassle, and encounter type were common explanations for underuse before the pandemic and continue to be widely cited during COVID-19. The legal imperative to use adequate interpretation services at every encounter should be better communicated to HCPs, and health systems should work to decrease barriers to interpreter services use. If third party interpretation presents the same barriers to use, healthcare systems should consider a strategic change to increase the bilingual work force and certify language skills so that patients can receive language-concordant care more consistently.

12.
Hormone Research in Paediatrics ; 95(SUPPL 1):90-91, 2022.
Article in English | Web of Science | ID: covidwho-1980852
13.
FEBS Open Bio ; 12:157-158, 2022.
Article in English | EMBASE | ID: covidwho-1976640

ABSTRACT

IGF (Insulin-like Growth Factor) system proteins, including their ligands IGF1 and IGF2, their receptor IGF1R and binding proteins (IGFBPs) that control their bioavailability, are involved in pulmonary homeostasis and in respiratory diseases, including COVID-19. However, their circulating levels have not yet been studied comparatively between groups of patients with different degrees of severity of the disease in order to determine their possible value as biomarkers in this context. Serum levels of IGF1, IGF2 and IGF1R were determined by ELISA, and those of IGFBP2, IGFBP3, IGFBP4 and IGFBP5 by immunoblotting. Results were compared between three groups of patients with different degrees of severity of COVID-19, and with those of an uninfected control group (total n = 120): uninfected (n = 24), asymptomatic (n = 32), hospitalized (n = 32) and ICU (n = 32) controls. IGFBP3/IGFBP2 ratios were also quantified. While IGF1 and IGF2 levels decreased in hospitalized and ICU patients, IGF1R levels were increased in ICU patients. IGFBP2 levels were also elevated in ICU patients, and conversely, IGFBP3 and IGFBP5 levels and IGFBP3/IGFBP2 ratios tend to decrease progressively with the severity of the disease. IGFBP4 levels were only significantly increased in the hospitalized patients compared to the control group. Changes in concentration levels of IGF1, IGF2, IGFBP3, and IGFBP5 follow similar patterns with a downward trend with COVID-19 severity, and are opposite to those of IGF1R and IGFBP2. IGFBP4 shows a different profile, being higher in hospitalized patients. Serum levels of IGFs change with the degree of COVID-19 and decreasing IGFBP3 and IGFBP5 levels and IGFBP3/IGFBP2 ratios show up as candidate biomarkers of disease severity.

14.
Revista Complutense de Educacion ; 33(3):447-458, 2022.
Article in Spanish | Scopus | ID: covidwho-1954587

ABSTRACT

Many authors consider death as something taboo in present-day society, but we do not know if this perception has been carried over to research on death from the educational point of view. To clarify this question, a review of publications in the last decade in the Dialnet and Scopus databases is presented. The results were analyzed from a quantitative and qualitative point of view in relation to the parameters of publication year, database, publication modality, journal title, audience, approach to Education for Death, resources proposed, and type and direction of the research. The results point to the publication of studies regarding the subject matter maintained over the period investigated, but with an unequal presence depending on whether it is the Dialnet database of greater informative character, or the Scopus database whose intention is related to quality standards. Among the conclusions, it is highlighted that Education for Death not only is not fashionable, but also maintains the interest throughout the years. However, the importance of this theme in the databases is reduced. It is proposed to incorporate reflective and critical perspectives in addition to practical techniques, as well as active initiatives to disseminate this knowledge. © 2022, Universidad Compultense Madrid. All rights reserved.

16.
Brazilian Journalism Research ; 18(1):182-213, 2022.
Article in English | Scopus | ID: covidwho-1912594

ABSTRACT

The research examines the methods in which social protest is criminalized through the media, as symbolic systems for the construction of reality that favor the control and reproduction of the social order. Based on the case study of the feminist demonstration on March 8, 2020, in Spain, the framing made by the newspapers El País, El Mundo, La Vanguardia, ABC and La Razón in their informative productions are analyzed. The observation period is between March 7 and June 21, 2020, when the first alarm state declared by the Spanish Government to fight the Covid-19 pandemic ended. The results show that beyond the editorial and ideological lines of these media, the feminist protest was mainly demonized by the framing identified in the texts, through the construction of a general idea of responsibility in the spread of the virus. © 2022 Associacao Brasileira de Pesquisadores de Jornalismo. All rights reserved.

17.
8th International Conference on Human Aspects of IT for the Aged Population, ITAP 2022, held as part of the 24th International Conference, HCI International 2022 ; 13331 LNCS:427-440, 2022.
Article in English | Scopus | ID: covidwho-1899002

ABSTRACT

The violence - without the apparent “Gender Peace”, if data and households are examined - occurs against adult and older women, is beginning to become apparent, but there is only information from recent years. The objective is demonstrate that social isolation can be a key factor in gender peace in the case of adult and older women, even more so in the case of disability or dependency situation. This work focuses on what we call older women gender peace based on qualitative techniques. Moreover, women in this vital stage continue to be vulnerable, defenseless, have more fear and risk, despite their plausible gender peace – expression that we contribute - which connects with the current post-health crisis scenario, armed violence and wars. This chapter also contributes to the consideration of technologies addressed to adults and older women to increase gender peace. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.

18.
European Urology ; 79:S1186, 2021.
Article in English | EMBASE | ID: covidwho-1747417

ABSTRACT

Introduction & Objectives: The TMPRSS2 protein has been found to be involved as a critical host cell factor in severe acute respiratory syndrome caused by coronavirus 2(SARS-CoV-2). The production of this protein is regulated by the androgen receptor (AR), also in non-prostatic tissues, including the lung. There is the speculation that androgen deprivation therapy (ADT) may protect patients affected by prostate cancer (PC) from SARS-CoV-2 infection. Our goal is to analyze the severity of COVID-19 in PC patients and the possible influence of ADT on this infection. Materials & Methods: Retrospective study of patients treated for COVID-19 between March 15th and May 15th 2020 in our institution who had previous diagnosis of PC. Patients were divided into two: Those treated with ADT during the infection or the year before, and those who were not treat with ADT on that period. Differences between groups in demographic characteristics, parameters of PC disease, risk factors for SARS-CoV-2 pneumonia, the presence of severe COVID-19 and mortality rates were analyzed. Results: During the study period, a total of 1365 patients were treated in our center for COVID-19 documented with positive PCR. From a total of 1349 subjects registered in our PC database, 156 were on ADT treatment and 1193 were not. Out of the total, 61 (4.52%) PC patients suffered from COVID-19, 11 (18.0%) belonged to the ADT group and 50(82.0%) to the non-ADT group. The mean age of the series was 77.6 years (SD:7.7). The cumulative incidence recorded of COVID-19 in total PC patients was 4.5% (95%CI: 3.5-5.8). Demographic variables, comorbidities and risk factors for infection were quite homogeneous in both groups. Although a worse tendency was observed in the non-ADT group, no statistically significant differences were found in any of the variables analyzed. Regarding the influence of ADT on the course of the disease, no statistically significant differences were found neither in the exitus rate (27.3% vs. 34.0%;p 0.481), nor in the presence of severe COVID-19: need for intubation or ICU admission(0% vs 6.3%;p 0.561) and need for corticoid treatment, interferon beta or tocilizumab (60% vs. 34.7%;p 0.128). In the univariate analysis, treatment with ADT was not found to be a protective factor for worse clinical evolution (RR 1.11;95%CI 0.67-1.85;p=0.68) or exitus (RR 0.8;95%CI 0.28-2.27;p=0.68). We also found no statistically significant differences when multivariate analysis adjusted for clinically relevant comorbidities was performed. Conclusions: In our study, the use of ADT has not been shown to be a protective factor against serious COVID-19. In view of the results published to date, more research in this area is definitely needed to draw firm conclusions.

19.
Open Forum Infectious Diseases ; 8(SUPPL 1):S382, 2021.
Article in English | EMBASE | ID: covidwho-1746438

ABSTRACT

Background. Optimal dose of methylprednisolone in patients with moderate or severe COVID-19 is unclear. In our hospital, the use of 250-500 mg/day of methylprednisolone was frequent in the first wave of the pandemic. Lower dose were recommended in our protocol since September 2020. The aim was to evaluate the impact of methylprednisolone dose in the outcome of patients with moderate or severe COVID-19. Methods. This is a retrospective and observational study. Inclusion criteria: SARS-CoV-2 infection diagnosed by PCR, admission to our hospital between March 2020 and February 2021, SatO2 < 94% or SatO2/FiO2 < 447. Two treatment groups were compared: patients treated with 0.5-1.5 mg/kg/day (group 1) and patients treated with more than 1.5 mg/kg/day (group 2). The primary outcome analyzed was orotracheal intubation (OTI) or death from any cause at 28 days after admission. Differences in demographic, clinical and laboratory characteristics between treatment groups were analyzed. Variables with P < 0.1 were included in a binary logistic regression model, calculating a propensity score for assigning each patient to group 1 treatment. Bivariate analysis was performed to identify variables associated with worst outcome. Finally, Cox regression was performed including treatment group, propensity score as covariate and all the variables with P< 0.05 in the bivariate analysis. Results. 285 patients were included, 197 in group 1 and 88 in group 2. The median age was 73 years, 52,3% were male. Mortality or OTI at 28 days was 24,9%. There was a higher proportion of patients in group 1 with COPD (9,6% vs 1.1%, P< 0.01), dyspnea (60.4% vs 45.5%, P=0.01), sepsis (22.8% vs 13.6%, P=0.07). Patients in group 2 had more impaired consciousness (18.2% vs 8.6%, P=0.02). The median of lymphocytes count was lower in group 1 (900 vs 1025, P=0.01). There were no differences in the primary outcome between treatment groups (26.1% in the group 2 vs 24.4% in the group 1, P=0.7). Conclusion. The use of high dose of methylprednisolone compared with intermediate dose is not associated with a better outcome in patients with moderate or severe COVID-19.

20.
SELECTION OF CITATIONS
SEARCH DETAIL